Voedingsgeneeskunde

NHG standaard Slaapproblemen en slaapmiddelen 2014

Gezondheidsenquête CBS 2018

Hammerschlag, Anke R., et al. Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits. Nature genetics, 2017, 49.11: 1584.

Allebrandt, K. V., et al. AK ATP channel gene effect on sleep duration: from genome-wide association studies to function in Drosophila. Molecular psychiatry, 2013, 18.1: 122.

Sack, R L., et al. Entrainment of free-running circadian rhythms by melatonin in blind people. New England Journal of Medicine, 2000, 343.15: 1070-1077.

Cajochen, C., et al. A. Role of melatonin in the regulation of human circadian rhythms and sleep. Journal of neuroendocrinology, 2003, 15.4: 432-437.

Arendt, J. Melatonin: characteristics, concerns, and prospects. Journal of Biological Rhythms, 2005, 20.4: 291-303.

Gooley, J.J., et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. The Journal of Clinical Endocrinology & Metabolism, 2011, 96.3: E463-E472.

Navara, K. J.; Nelson, R. J. The dark side of light at night: physiological, epidemiological, and ecological consequences. Journal of pineal research, 2007, 43.3: 215-224.

Kantermann,T., Roennenberg, T. Is light-at-night a health risk factor or a health risk predictor?. Chronobiology international, 2009, 26.6: 1069-1074.

Stevens, R. G.; Zhu, Y. Electric light, particularly at night, disrupts human circadian rhythmicity: is that a problem?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370.1667: 20140120.

EFSA PoDPNaAN. Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698,1780,4080) pursuant to Article 13(1) of Regulation (EC) No 1924 / 2006. EFSA J 2011;9(2241).

Lewy, A. J.; Sack, R. L. The dim light melatonin onset as a marker for orcadian phase position. Chronobiology international, 1989, 6.1: 93-102.

Keijzer H, Smits MG, Peeters T, Looman CW, Endenburg SC, Gunnewiek JM. Evaluation of salivary melatonin measurements for Dim Light Melatonin Onset calculations in patients with possible sleep-wake rhythm disorders. Clin Chim Acta 2011;412(17-18):1616-20.

Keijzer H, Smits MG, Duffy JF, Curfs LM. Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Med Rev 2014;18(4):333-9.

Sletten TL, Magee M, Murray JM, Gordon CJ, Lovato N, Delayed Sleep on Melatonin (DelSoM) Study Group. Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial. PLoS Med. 2018 Jun 18;15(6):e1002587

Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41-50.

Auld, F., et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Medicine Reviews, 2017, 34: 10-22.

Buscemi, N., et al. The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis. Journal of general internal medicine, 2005, 20.12: 1151-1158.

Buscemi, N., et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. Bmj, 2006, 332.7538: 385-393.

Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;

Herxheimer, A.; Petrie, K.J. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev, 2002, 2.

Gezondheidsrisico’s door nachtwerk Aan: de minister van Sociale Zaken en WerkgelegenheidNr. 2017/17, Den Haag 24 oktober 2017

Bruni O, Alonso-Alconada D, Besag F, et al. Current role ofmelatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol 2015;19:122-33.

Gordijn, M.C.M., Melatoninebehandeling voor slaap-waakstoornissen. Psyfar nr 1 , maart 2018 |

Benloucif S, Burgess HJ, Klerman EB, et al. Measuring melatonin in humans. J. Clin Sleep Med 2008;4(1):66-9.

Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. JCEM 2010;95:3325-31.

Lewy AJ, Bauer VK, Ahmed S, Thomas KH, Cutler NL, Singer CM, Moffit MT, Sack RL 1998 The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int 15:71–83

Romero, K., et al. Alternative remedies for insomnia: a proposed method for personalized therapeutic trials. Nature and science of sleep, 2017, 9: 97.

Braam W, van G, I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res 2010;54(6):547-55.

Braam W, Keijzer H, Struijker BH, Didden R, Smits M, Curfs L. CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder? J Intellect Disabil Res 2012.

van Geijlswijk IM, et al., Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology (Berl) 2010;212:379-91.

Cummings C. Melatonin for the management of sleep disorders in children and adolescents. Paediatr Child Health 2012;17:331-6.

National Institute for Health and Care Excellence. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2) 2013.

Bruni O, Novelli L. Sleep disorders in children. Clin Evid(Online) 2010:2304